Table 1.
Baseline characteristics (at enrollment) of the pediatric‐onset MS cases and controls included in the Trp metabolites analysis (non‐targeted assays)
| MS Cases | Control | P‐value1 | |
|---|---|---|---|
| N | 69 | 67 | |
| Age in years, mean (SD) | 14.3 (2.8) | 14.5 (2.6) | 0.63 |
| Female (%) | 32 (46%) | 32 (48%) | 0.87 |
| Race/ethnicity (%) | |||
| White, non‐Hispanic | 36 (52%) | 36 (54%) | 0.92 |
| White, Hispanic | 22 (32%) | 22 (33%) | |
| Black | 5 (7%) | 3 (4%) | |
| Others | 6 (9%) | 6 (9%) | |
| 25(OH) vitamin D in ng/mL, mean (SD) | 24.5 (9.8) | 23.5 (8.8) | 0.55 |
| DMT exposed (%) | 50 (74) | N/A | – |
| Follow‐up duration in years, mean (SD) | 3.2 (1.8) | N/A | – |
| Median EDSS (IQR) | 3 (2–4) | N/A | – |
| Mean SDMT (SD) | 53.2 (15.1) [32 out of 69 patients had scores available] | N/A | – |
DMT, disease‐modifying therapy.
1Student T‐test for continuous variables and chi‐square test for categorical variables.